Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Aligos HDV ASO
- Development stage
- Preclinical
- Lead developer
- Aligos Therapeutics
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Aligos Therapeutics is developing a proprietary antisense oligonucleotide (ASO) program targeting the hepatitis delta virus (HDV) genome. HDV infection typically occurs as a coinfection with hepatitis B virus (HBV) and is associated with more severe liver disease. This ASO is designed to bind to and trigger the destruction of the viral genome, which the company describes as uniquely suited toward a potential HDV cure strategy. As of late 2025, the program is in the preclinical stage, with ongoing work aimed at selecting a clinical development candidate. The program has been presented at scientific meetings such as the 2025 International HBV Meeting and HEP-DART 2025.
- Other names
- Aligos Therapeutics-HDV genome-ASO-Hepatitis Delta VirusHDV-targeted ASO clinical development candidate
02
Targets
HDV RNA (Hepatitis delta virus RNA)
Beyond the preview
Go deeper on Aligos HDV ASO.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aligos HDV ASO.